183 related articles for article (PubMed ID: 3126410)
1. Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures.
Gal P; Oles KS; Gilman JT; Weaver R
Neurology; 1988 Mar; 38(3):467-71. PubMed ID: 3126410
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children.
Panomvana Na Ayudhya D; Suwanmanee J; Visudtibhan A
Am J Ther; 2006; 13(3):211-7. PubMed ID: 16772762
[TBL] [Abstract][Full Text] [Related]
3. Free and total serum valproate concentrations: their relationship to seizure control, liver enzymes and plasma ammonia in children.
Farrell K; Abbott FS; Orr JM; Applegarth DA; Jan JE; Wong PK
Can J Neurol Sci; 1986 Aug; 13(3):252-5. PubMed ID: 3091231
[TBL] [Abstract][Full Text] [Related]
4. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study.
Coppola G; Auricchio G; Federico R; Carotenuto M; Pascotto A
Epilepsia; 2004 Sep; 45(9):1049-53. PubMed ID: 15329068
[TBL] [Abstract][Full Text] [Related]
5. Correlation between plasma ammonia level and serum trough concentration of free valproic acid in patients with epilepsy.
Itoh H; Suzuki Y; Fujisaki K; Sato Y; Takeyama M
Biol Pharm Bull; 2012; 35(6):971-4. PubMed ID: 22687541
[TBL] [Abstract][Full Text] [Related]
6. Drug treatment of epilepsy in elderly people: focus on valproic Acid.
Stephen LJ
Drugs Aging; 2003; 20(2):141-52. PubMed ID: 12534314
[TBL] [Abstract][Full Text] [Related]
7. Valproic acid and secondary hyperammonemia.
Rawat S; Borkowski WJ; Swick HM
Neurology; 1981 Sep; 31(9):1173-4. PubMed ID: 6791053
[TBL] [Abstract][Full Text] [Related]
8. Lack of pharmacokinetic interaction between valproic acid and a traditional Chinese medicine, Paeoniae Radix, in healthy volunteers.
Chen LC; Chou MH; Lin MF; Yang LL
J Clin Pharm Ther; 2000 Dec; 25(6):453-9. PubMed ID: 11123499
[TBL] [Abstract][Full Text] [Related]
9. Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus.
Hovinga CA; Chicella MF; Rose DF; Eades SK; Dalton JT; Phelps SJ
Ann Pharmacother; 1999 May; 33(5):579-84. PubMed ID: 10369622
[TBL] [Abstract][Full Text] [Related]
10. Free valproic acid: steady-state pharmacokinetics in patients with intractable epilepsy.
Otten N; Hall K; Irvine-Meek J; Leroux M; Budnik D; Seshia S
Can J Neurol Sci; 1984 Nov; 11(4):457-60. PubMed ID: 6440705
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of total and free valproic acid during monotherapy in infants.
Herngren L; Lundberg B; Nergårdh A
J Neurol; 1991 Sep; 238(6):315-9. PubMed ID: 1940980
[TBL] [Abstract][Full Text] [Related]
12. Serum biotinidase activity in children treated with valproic acid and carbamazepine.
Castro-Gago M; Gómez-Lado C; Eirís-Puñal J; Díaz-Mayo I; Castiñeiras-Ramos DE
J Child Neurol; 2010 Jan; 25(1):32-5. PubMed ID: 19458381
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of a continuous intravenous infusion of valproic acid in pediatric patients.
Taylor LM; Farzam F; Cook AM; Lewis DA; Baumann RJ; Kuhn RJ
Pharmacotherapy; 2007 Apr; 27(4):519-25. PubMed ID: 17381378
[TBL] [Abstract][Full Text] [Related]
14. Studies on the pharmacokinetics of total and free valproate in mono- and bitherapy with carbamazepine in epileptic children and adolescents.
Steinborn B; Galas-Zgorzalewicz B
Folia Neuropathol; 2002; 40(2):97-100. PubMed ID: 12230261
[TBL] [Abstract][Full Text] [Related]
15. Differential ammonia decay kinetics indicates more than one concurrent etiological mechanism for symptomatic hyperammonemia caused by valproate overdose.
Mojumder DK; De Oleo RR
Indian J Pharmacol; 2014; 46(3):345-7. PubMed ID: 24987188
[TBL] [Abstract][Full Text] [Related]
16. Gait instability in valproate-treated patients: Call to measure ammonia levels.
Kipervasser S; Elger CE; Korczyn AD; Nass RD; Quesada CM; Neufeld MY
Acta Neurol Scand; 2017 Nov; 136(5):401-406. PubMed ID: 28436001
[TBL] [Abstract][Full Text] [Related]
17. Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy.
Galimberti CA; Mazzucchelli I; Arbasino C; Canevini MP; Fattore C; Perucca E
Epilepsia; 2006 Sep; 47(9):1569-72. PubMed ID: 16981874
[TBL] [Abstract][Full Text] [Related]
18. [Hyperammonemia in valproate therapy in children and adolescents].
Laub MC
Nervenarzt; 1986 May; 57(5):314-8. PubMed ID: 3088461
[TBL] [Abstract][Full Text] [Related]
19. Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients.
Goto S; Seo T; Hagiwara T; Ueda K; Yamauchi T; Nagata S; Ando Y; Ishitsu T; Nakagawa K
J Pharm Pharmacol; 2008 Feb; 60(2):267-72. PubMed ID: 18237476
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and clinical application of intravenous valproate in Thai epileptic children.
Visudtibhan A; Bhudhisawadi K; Vaewpanich J; Chulavatnatol S; Kaojareon S
Brain Dev; 2011 Mar; 33(3):189-94. PubMed ID: 20444563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
